Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review

REFERENCES

• Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G; Writing Protocol Committee; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain. 2011;27:9–18.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. The Cochrane Collaboration; 2008. Available at: www.cochrane-handbook.org. Accessed May 2014.
   Google Scholar
• Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805–811.
   PubMed Web of Science ®Google Scholar
• Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327–334.
   PubMedGoogle Scholar
• Weinstein S, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain. Cancer. 2009;115:2571–2579.
   PubMed Web of Science ®Google Scholar
• Zeppetella G, Messina J, Xie F, Slatkin NE. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Pract. 2010;10:287–293.
   PubMed Web of Science ®Google Scholar
• Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611–616.
   PubMed Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral trnasmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (IRMS). Pain. 2001;91:123–130.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P, Casuccio A, Mangione S, Intravaia G. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer. 2007;96:1828–1833.
   PubMed Web of Science ®Google Scholar
• Zarth R. Comparison of buprenorphine, morphine sulphate and fentanyl citrate as rescue medication for breakthrough pain in cancer patients. J Appl Ther Res. 2008;6:15–19.
   Google Scholar
• Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805–2815.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999;79:303–312.
   PubMed Web of Science ®Google Scholar
• Christie JM, Simmonds M, Patt R, et al. Dose titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998;16: 3238–3245.
   PubMed Web of Science ®Google Scholar
• Lennernas B, Frank-Lissbrant I, Lennernäs H, Kälkner KM, Derrick R, Howell J. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010;24:286–293.
   PubMed Web of Science ®Google Scholar
• Rauk R, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877–2885.
   PubMed Web of Science ®Google Scholar
• Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo controlled study. Ann Oncol. 2010;21:1308–1314.
   PubMed Web of Science ®Google Scholar
• Kress HG, Ororiska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 mg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a l-month, open-label extension treatment period. Clin Ther. 2009;31:1177–1191.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Burton AW, Gabrail N, Taylor D, on behalf of the Fentanyl Pectin Nasal Spray 043 Study Group. A multicenter, placebo-controlled, double-blind, multiple crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617–624.
   PubMed Web of Science ®Google Scholar
• Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R; Fentanyl Pectin Nasal Spray 043 Study Group. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol. 2010;8:184–190.
   PubMedGoogle Scholar
• Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage. 2011;41:358–366.
   PubMed Web of Science ®Google Scholar
• Fallon M, Reale C, Davies A, et al.; Fentanyl Nasal Spray Study 044 Investigators Group. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224–231.
   PubMedGoogle Scholar
• Radbruch L, Torres LM, Ellershaw JE, et al. Long term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer. 2012;20:565–573.
   PubMed Web of Science ®Google Scholar
• Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag. 2010;6:17–26.
   PubMedGoogle Scholar